Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Vascular · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 60%Low 1 · 20%Moderate 1 · 20%High 0 · 0%

Intervention not reported

Bleeding (early, up to 1 month after treatment) · patients diagnosed with acute DVT

The intervention probably leads to higher bleeding (early, up to 1 month after treatment) (moderate certainty).

1 finding from 1 review

Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb 2021 · Cochrane Headline outcomes only
RR 2.45 [1.58, 3.78]
19 studies · 1943 participants
Moderate

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone

Mortality ‐ early and intermediate · people requiring treatment for chronic DVT

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 224 participants
Very low

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP plus placebo

Recurrent VTE · people requiring treatment for chronic DVT

Chronic DVT ‐ antiplatelet agents plus BMP may leads to lower recurrent VTE ‐ early, intermediate and long term compared with BMP plus placebo (low certainty).

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
RR 0.65 [0.43, 0.96]
4 studies · 901 participants
Low

Acute DVT ‐ antiplatelet agents plus BMP vs BMP alone

Mortality ‐ early and intermediate · people requiring treatment for acute DVT

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 500 participants
Very low

Chronic DVT ‐ antiplatelet agents plus BMP vs BMP alone

Recurrent VTE ‐ early and intermediate · people requiring treatment for chronic DVT

It is very uncertain whether chronic DVT ‐ antiplatelet agents plus BMP changes recurrent VTE ‐ early and intermediate compared with BMP alone (very low certainty).

1 finding from 1 review

Antiplatelet agents for the treatment of deep venous thrombosis 2022 · Cochrane Headline outcomes only
RR 0.12 [0.05, 0.34]
1 study · 224 participants
Very low